Kymera Therapeutics

Kymera Therapeutics Announces Third Quarter 2020 Financial Results and Provides Business Update

Well positioned to advance a leading pipeline of targeted protein degradation medicines with recent completion of upsized initial public offering and strategic collaboration with Sanofi Reported positive interim results from non-interventional study o f KT-474 (IRAK4 degrader) in HS patients and